Published in J Immunol on December 30, 2009
Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell (2012) 3.24
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 2.15
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Leptin signaling in intestinal epithelium mediates resistance to enteric infection by Entamoeba histolytica. Mucosal Immunol (2010) 1.76
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
Oral lichen planus as a preneoplastic inflammatory model. J Biomed Biotechnol (2012) 1.15
Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS One (2011) 1.06
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res (2013) 1.02
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer (2013) 1.01
The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone. J Biol Chem (2013) 1.00
Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS One (2012) 0.98
Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol (2014) 0.97
Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis. Mucosal Immunol (2015) 0.93
Pericellular proteolysis in cancer. Genes Dev (2014) 0.92
IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One (2014) 0.92
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep (2015) 0.92
Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.91
Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol (2014) 0.89
Trp53 deficiency protects against acute intestinal inflammation. J Immunol (2013) 0.86
Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med (2011) 0.86
Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis Mice. Int J Inflam (2014) 0.84
Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor. Anticancer Agents Med Chem (2012) 0.84
Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology (2014) 0.84
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget (2016) 0.83
Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn J Ophthalmol (2011) 0.82
ADAM Proteases and Gastrointestinal Function. Annu Rev Physiol (2015) 0.81
Stat3: friend or foe in colitis and colitis-associated cancer? Inflamm Bowel Dis (2014) 0.80
Recent advancement in understanding colitis-associated tumorigenesis. Inflamm Bowel Dis (2014) 0.79
Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells. BMC Cancer (2015) 0.79
Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol (2017) 0.77
PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer. Int J Clin Exp Pathol (2015) 0.77
15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway. FASEB J (2015) 0.77
Functions and regulation of MUC13 mucin in colon cancer cells. J Gastroenterol (2013) 0.77
Mechanisms of Immune Signaling in Colitis-Associated Cancer. Cell Mol Gastroenterol Hepatol (2014) 0.77
Gut microbiota and colorectal cancer. Genes Environ (2016) 0.77
cEBP Homologous Protein Expression in Macrophages Regulates the Magnitude and Duration of IL-6 Expression and Dextran Sodium Sulfate Colitis. J Interferon Cytokine Res (2015) 0.76
CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer. Int J Cancer (2015) 0.76
Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repair. Oncogenesis (2016) 0.75
Interleukin-6 "Trans-Signaling" and Ischemic Vascular Disease: The Important Role of Soluble gp130. Mediators Inflamm (2017) 0.75
Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol (2017) 0.75
Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica (2016) 0.75
Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: An immunohistochemical study. Med Oral Patol Oral Cir Bucal (2016) 0.75
Interleukin-6 (IL-6) mediated the increased contraction of distal colon in streptozotocin-induced diabetes in rats via IL-6 receptor pathway. Int J Clin Exp Pathol (2015) 0.75
Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy. Mol Vis (2016) 0.75
Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer. J Crohns Colitis (2012) 0.75
STAT3 and NF-κB are common targets for kaempferol-mediated attenuation of COX-2 expression in IL-6-induced macrophages and carrageenan-induced mouse paw edema. Biochem Biophys Rep (2017) 0.75
Role of ADAM10 in Intestinal Crypt Homeostasis and Tumorigenesis. Biochim Biophys Acta (2017) 0.75
Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis. PLoS One (2017) 0.75
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 5.72
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol (2004) 3.51
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 3.51
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol (2006) 3.45
Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol (2002) 3.35
CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med (2006) 3.11
Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol (2004) 3.03
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 3.01
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol (2003) 2.91
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol (2004) 2.81
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology (2009) 2.48
Yeast Mph1 helicase dissociates Rad51-made D-loops: implications for crossover control in mitotic recombination. Genes Dev (2009) 2.43
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med (2002) 2.23
ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol (2011) 2.19
The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol (2004) 2.19
IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res (2005) 2.17
The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets (2007) 2.17
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer (2002) 2.13
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol (2005) 2.07
Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol (2008) 2.06
Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol (2006) 2.05
Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem (2003) 2.05
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 1.92
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med (2011) 1.87
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol (2004) 1.83
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology (2002) 1.79
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol (2008) 1.78
Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells (2004) 1.73
Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Appl Environ Microbiol (2009) 1.71
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest (2003) 1.69
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 1.65
G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol (2009) 1.65
Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol (2007) 1.65
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol (2004) 1.62
Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood (2010) 1.56
The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta (2002) 1.53
Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology (2011) 1.52
General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc (2010) 1.51
Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol (2003) 1.51
Identification of proteins phosphorylated directly by the Us3 protein kinase encoded by herpes simplex virus 1. J Virol (2005) 1.50
Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment. Acta Haematol (2006) 1.50
Atypical manifestations of pancreatitis with autoimmune phenomenon in an adolescent female. Intern Med (2005) 1.50
IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol (2008) 1.48
L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol (2005) 1.47
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol (2007) 1.47
Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol (2004) 1.46
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol (2007) 1.46
A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol (2009) 1.46
SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med (2004) 1.46
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med (2010) 1.45
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. J Gastroenterol (2004) 1.43
Prebiotic treatment in experimental colitis reduces the risk of colitic cancer. J Gastroenterol Hepatol (2011) 1.43
Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res (2006) 1.42
In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin Exp Pharmacol Physiol (2013) 1.41
IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol (2010) 1.39
Current status in the occurrence of postoperative bleeding, perforation and residual/local recurrence during colonoscopic treatment in Japan. Dig Endosc (2010) 1.38
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci (2009) 1.37
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2007) 1.37
Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol (2010) 1.36
The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol (2010) 1.35
JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc (2015) 1.35
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol (2009) 1.35
Herpes simplex virus 1-encoded protein kinase UL13 phosphorylates viral Us3 protein kinase and regulates nuclear localization of viral envelopment factors UL34 and UL31. J Virol (2006) 1.33